Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) EBT (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of EBT data on record, last reported at -$63.0 million in Q4 2025.

  • For Q4 2025, EBT fell 36.76% year-over-year to -$63.0 million; the TTM value through Dec 2025 reached -$235.0 million, up 10.14%, while the annual FY2025 figure was -$235.0 million, 10.14% up from the prior year.
  • EBT reached -$63.0 million in Q4 2025 per MRVI's latest filing, down from -$45.1 million in the prior quarter.
  • Across five years, EBT topped out at $656.2 million in Q4 2023 and bottomed at -$172.1 million in Q3 2024.
  • Average EBT over 5 years is $60.2 million, with a median of -$8.9 million recorded in 2023.
  • Peak YoY movement for EBT: skyrocketed 21425.85% in 2021, then crashed 737.15% in 2024.
  • A 5-year view of EBT shows it stood at $144.7 million in 2021, then crashed by 33.74% to $95.9 million in 2022, then soared by 584.41% to $656.2 million in 2023, then tumbled by 107.02% to -$46.1 million in 2024, then tumbled by 36.76% to -$63.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were -$63.0 million in Q4 2025, -$45.1 million in Q3 2025, and -$74.1 million in Q2 2025.